Zacks Research Has Positive Outlook for CVKD FY2026 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities research analysts at Zacks Research lifted their FY2026 earnings per share estimates for Cadrenal Therapeutics in a research report issued on Friday, May 8th. Zacks Research analyst D. Bautz now expects that the company will post earnings per share of ($4.82) for the year, up from their prior estimate of ($5.08). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($5.61) per share.

A number of other brokerages also recently commented on CVKD. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. Finally, HC Wainwright decreased their target price on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cadrenal Therapeutics presently has an average rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Trading Down 6.0%

Shares of CVKD opened at $5.19 on Wednesday. The company has a market capitalization of $14.88 million, a price-to-earnings ratio of -0.92 and a beta of 1.81. The stock has a 50 day moving average of $6.02 and a 200 day moving average of $7.86. Cadrenal Therapeutics has a 12 month low of $4.21 and a 12 month high of $16.25.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.47.

Institutional Trading of Cadrenal Therapeutics

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in Cadrenal Therapeutics in the third quarter worth $103,000. Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics in the third quarter worth $274,000. DRW Securities LLC purchased a new stake in Cadrenal Therapeutics in the fourth quarter worth $171,000. Finally, Geode Capital Management LLC increased its position in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after buying an additional 1,818 shares during the last quarter. 7.92% of the stock is owned by hedge funds and other institutional investors.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.